Skip to main content

Table 3 BCL9 CN gain in HCC patients according to early and late HCC stages

From: The role of BCL9 genetic variation as a biomarker for hepatitis C-related hepatocellular carcinoma in Egyptian patients

CNV

Early HCC patients, N = 25

Late HCC patients, n = 25

P-value

Gain

3 (12.0%)

4 (16.0%)

1.00

No gain

22 (88.0%)

21 (84.0%)